ginsenoside Rh2, ginsenoside-Rh2
Name | Ginsenoside Rh2 | ||
PubChem CID | 119307 | ||
Molecular Weight | 622.9g/mol | ||
Synonyms |
ginsenoside Rh2, ginsenoside-Rh2 |
||
Formula | C₃₆H₆₂O₈ | ||
SMILES | CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)O)C)C)O)C)O)C | ||
InChI | 1S/C36H62O8/c1-20(2)10-9-14-36(8,42)21-11-16-35(7)27(21)22(38)18-25-33(5)15-13-26(32(3,4)24(33)12-17-34(25,35)6)44-31-30(41)29(40)28(39)23(19-37)43-31/h10,21-31,37-42H,9,11-19H2,1-8H3/t21-,22+,23+,24-,25+,26-,27-,28+,29-,30+,31-,33-,34+,35+,36-/m0/s1 | ||
InChIKey | CKUVNOCSBYYHIS-IRFFNABBSA-N | ||
CAS Number | 78214-33-2 | ||
ChEMBL ID | CHEMBL1783834 | ||
ChEBI ID | CHEBI:77147 | ||
KEGG ID | C22128 | ||
Structure |
Download
2D
MOL
3D
MOL
|
Chineses Pinyin | RenShen | ||
Use Part | Root | ||
Habitat | JiLin, LiaoNing, HeiLongJiang | ||
Flavor | Sweet; Slightly Bitter | ||
Meridian Tropism | Spleen; Lung; Heart; Kidney | ||
Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Apiales
-->Family: Araliaceae
-->Genus: Panax
-->Species: Panax ginseng
|
Pair Name | Ginsenoside Rh2, Gemcitabine | |||
Partner Name | Gemcitabine | |||
Disease Info | [ICD-11: 2C10] | Pancreatic cancer | Investigative | |
Biological Phenomena | Induction-->Immunomodulatory | |||
Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
Up-regulation | Expression | BCL10 | hsa8915 | |
Down-regulation | Expression | BCL2 | hsa596 | |
Up-regulation | Expression | CARD9 | hsa64170 | |
Up-regulation | Cleavage | CASP3 | hsa836 | |
Up-regulation | Expression | MALT1 | hsa10892 | |
Up-regulation | Expression | NFKB1 | hsa4790 | |
In Vitro Model | Panc02 | Mouse pancreatic ductal adenocarcinoma | Mus musculus (Mouse) | CVCL_D627 |
PANC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0480 | |
In Vivo Model | Orthotopic mouse model: Panc02 cells engineered to stably express firefly luciferase (1×10⁶) were mixed in an equal volume of Matrigel and were injected into the tail of pancreas of each mouse. | |||
Result | Rh2 activation of DCs may remodel the cold TIME and optimize GEM chemotherapy for future therapeutic use. |
Pair Name | Ginsenoside Rh2, Sodium selenite | |||
Partner Name | Sodium selenite | |||
Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
Biological Phenomena | Induction-->Blockade of cell cycle in G1/S phase | |||
Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
Down-regulation | Expression | BCL2 | hsa596 | |
Up-regulation | Expression | CASP3 | hsa836 | |
In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
Result | Sodium selenite and G-Rh2 combination have a synergistic effect on cell growth inhibition (57%) compared with sodium selenite (25%) and G-Rh2 alone (28%) after 24 hours of treatment |
Pair Name | Ginsenoside Rh2, Anti-PD-L1 antibody | |||
Partner Name | Anti-PD-L1 antibody | |||
Disease Info | [ICD-11: 2A00-2F9Z] | Solid tumour or cancer | Investigative | |
Biological Phenomena | Induction-->Immunomodulatory | |||
Gene Regulation | Up-regulation | Expression | IRF1 | hsa3659 |
Up-regulation | Phosphorylation | IRF3 | hsa3661 | |
Up-regulation | Phosphorylation | STAT1 | hsa6772 | |
Up-regulation | Phosphorylation | TBK1 | hsa29110 | |
In Vitro Model | MC-38 | Mouse colon adenocarcinoma | Mus musculus (Mouse) | CVCL_B288 |
CT26 | Mouse colon adenocarcinoma | Mus musculus (Mouse) | CVCL_7254 | |
4T1 | Malignant neoplasms of the mouse mammary gland | Mus musculus (Mouse) | CVCL_0125 | |
In Vivo Model | The right flank of C57BL/6 mice were received with the subcutaneous injection of 1×10⁶ MC38 cells,2.5×105 4T1 cells or 1×10⁶ CT26 cells were subcutaneously injected into the right flank of BALB/c mice. | |||
Result | These findings demonstrated that Rh2 potentiated the anti-cancer effect of PD-L1 blockade via promoting the T cells infiltration and activation, which shed a new light on the combination strategy to enhance anti-PD-L1 immunotherapy by using natural product Rh2. |
Pair Name | Ginsenoside Rh2, Doxorubicin | |||
Partner Name | Doxorubicin | |||
Disease Info | [ICD-11:2D40] | Ehrlich's adenocarcinoma | Investigative | |
Gene Regulation | Up-regulation | Expression | NFE2L2 | hsa4780 |
In Vivo Model | CD-1 albino mice were inoculated intraperitoneally (i.p.) with 0.5 mL PBS containing 3×10⁶ cells of Ehrlich’s adenocarcinoma (cells were derived from 7-day-old tumor re-transplanted into CD-1 mice). | |||
Result | Rh2-induced direct activation of Nrf2 might provide additional benefits by minimizing DOX toxicity towards non-cancerous cells. |
No. | Title | Href |
---|---|---|
1 | Probable Mechanisms of Doxorubicin Antitumor Activity Enhancement by Ginsenoside Rh2. Molecules. 2022 Jan 19;27(3):628. doi: 10.3390/molecules27030628. | Click |
2 | The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic cancer via the CARD9-BCL10-MALT1 / NF-κB pathway. Clin Immunol. 2023 Mar;248:109217. doi: 10.1016/j.clim.2022.109217. | Click |
3 | Combined Effect of Sodium Selenite and Ginsenoside Rh2 on HCT116 Human Colorectal Carcinoma Cells. Arch Iran Med. 2016 Jan;19(1):23-9. | Click |
4 | Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10. Pharmacol Res. 2023 Dec;198:106988. doi: 10.1016/j.phrs.2023.106988. | Click |